Literature DB >> 8126763

Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intravenous and oral administration of enrofloxacin in dogs.

K Küng1, J L Riond, M Wanner.   

Abstract

Four dogs were given 5 mg/kg body weight enrofloxacin intravenously (i.v.) and orally (p.o.) in a cross-over study. Plasma concentrations of the active ingredient enrofloxacin and its main metabolite ciprofloxacin were determined by a reversed phase liquid chromatographic method. Pharmacokinetic parameters of both substances were calculated by use of statistical moments and were compared to those of enrofloxacin described in the veterinary literature. Mean enrofloxacin t1/2 lambda z was 2.4 h, mean Cls was 27.1 ml/min.kg, and mean Vss was 7.0 l/kg. After i.v. and p.o. administration, concentrations of ciprofloxacin exceeding minimal inhibitory concentrations of several microorganisms were reached (Cmax = 0.2 microgram/ml, tmax = 2.2 h after intravenous administration; Cmax = 0.2 microgram/ml, tmax = 3.6 h after oral administration). A considerable part of the antimicrobial activity is due to ciprofloxacin, the main metabolite of enrofloxacin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8126763     DOI: 10.1111/j.1365-2885.1993.tb00212.x

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  15 in total

1.  Pharmacokinetics and dosage regimen of enrofloxacin in buffalo bulls after intramuscular administration.

Authors:  H K Verma; G R Pangawkar; R K Chaudhary; A K Srivastava
Journal:  Vet Res Commun       Date:  1999-12       Impact factor: 2.459

2.  Identification of multiresistant Salmonella isolates capable of subsisting on antibiotics.

Authors:  Alison E Barnhill; Katherine E Weeks; Nalee Xiong; Tim A Day; Steve A Carlson
Journal:  Appl Environ Microbiol       Date:  2010-02-19       Impact factor: 4.792

3.  Residues of fluoroquinolones in marine aquaculture environment of the Pearl River Delta, South China.

Authors:  Xiuting He; Zhaohui Wang; Xiangping Nie; Yufen Yang; Debo Pan; Anna O W Leung; Zhang Cheng; Yongtao Yang; Kaibin Li; Kunci Chen
Journal:  Environ Geochem Health       Date:  2011-09-01       Impact factor: 4.609

4.  The plasma kinetics and tissue distribution of enrofloxacin and its metabolite ciprofloxacin in the Muscovy duck.

Authors:  L Intorre; G Mengozzi; S Bertini; M Bagliacca; E Luchetti; G Soldani
Journal:  Vet Res Commun       Date:  1997-02       Impact factor: 2.459

5.  Pharmacokinetic disposition of subcutaneously administered enrofloxacin in goats.

Authors:  S Ramesh; G S Rao; J K Malik
Journal:  Vet Res Commun       Date:  2002-10       Impact factor: 2.459

6.  Pharmacokinetics of enrofloxacin after intravenous and intramuscular administration in Angora goats.

Authors:  M Elmas; B Tras; S Kaya; A L Bas; E Yazar; E Yarsan
Journal:  Can J Vet Res       Date:  2001-01       Impact factor: 1.310

7.  Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intramuscular administration of enrofloxacin in goats.

Authors:  G S Rao; S Ramesh; A H Ahmad; H C Tripathi; L D Sharma; J K Malik
Journal:  Vet Res Commun       Date:  2001-04       Impact factor: 2.459

8.  Polymyxin B in Combination with Enrofloxacin Exerts Synergistic Killing against Extensively Drug-Resistant Pseudomonas aeruginosa.

Authors:  Yu-Wei Lin; Heidi H Yu; Jinxin Zhao; Mei-Ling Han; Yan Zhu; Jesmin Akter; Hasini Wickremasinghe; Hasini Walpola; Veronika Wirth; Gauri G Rao; Alan Forrest; Tony Velkov; Jian Li
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

9.  The antimicrobial susceptibility of Staphylococcus species isolated from canine dermatitis.

Authors:  H Kruse; M Hofshagen; S I Thoresen; W P Bredal; I Vollset; N E Søli
Journal:  Vet Res Commun       Date:  1996       Impact factor: 2.459

10.  Fluoroquinolone-mediated inhibition of cell growth, S-G2/M cell cycle arrest, and apoptosis in canine osteosarcoma cell lines.

Authors:  Kyoung won Seo; Roseline Holt; Yong-Sam Jung; Carlos O Rodriguez; Xinbin Chen; Robert B Rebhun
Journal:  PLoS One       Date:  2012-08-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.